PDCD1 and neoplasm: Immune checkpoint blockade (ICB) therapies, particularly those targeting the programmed cell death protein 1 (PD-1) and its ligand PD-L1, have revolutionized cancer treatment by restoring anti-tumor immunity in a subset of patients (1).